Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PD-1 monoclonal antibody after surgery for hepatocellular carcinoma with microvascular invasion
ChiCTR2000037655Phase 2Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Routine follow-up (observation) with Adjuvant sintilimab (2 arms). Primary endpoint: Relapse-free survival (RFS). Started Sep 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000037655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037655.